Related Experiment Video
Updated: Jun 21, 2026
09:57
In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
Published on: March 5, 2019
WITHDRAWN: Corticosteroids for HELLP syndrome in pregnancy
Patrice T Matchaba1, Jagidesa Moodley
1Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, USA.
The Cochrane Database of Systematic Reviews
|July 10, 2009
Summary
Corticosteroid treatment for HELLP syndrome showed no significant impact on maternal or infant mortality. However, dexamethasone may improve some maternal health indicators and increase birth weight, though evidence is limited.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Pharmacology in Pregnancy
Background:
- HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe pregnancy complication linked to pre-eclampsia.
- It significantly increases maternal and perinatal morbidity and mortality, often presenting before term.
- Observational studies suggest corticosteroids may improve maternal hematological/biochemical markers and perinatal outcomes.
Purpose of the Study:
- To systematically review evidence on the efficacy of corticosteroids in managing HELLP syndrome.
- To evaluate the impact of steroid therapy on maternal and neonatal mortality and morbidity.
Main Methods:
- Searched the Cochrane Pregnancy and Childbirth Group trials register and reference lists.
- Included randomized and quasi-randomized trials of adjunctive corticosteroids for HELLP syndrome.
- Two independent reviewers assessed eligibility, quality, and extracted data.
Main Results:
- Five studies (n=170) were reviewed; four compared dexamethasone with standard therapy, one compared dexamethasone with betamethasone.
- Dexamethasone showed no significant difference in primary maternal mortality/morbidity but improved platelet counts, reduced hospital stay, and delayed delivery.
- No significant differences in perinatal mortality/morbidity were observed; however, dexamethasone was associated with greater birth weight and improved maternal oliguria, blood pressure, and liver enzymes.
Conclusions:
- Current evidence is insufficient to definitively conclude whether adjunctive steroid use reduces maternal and perinatal mortality or major morbidity in HELLP syndrome.
- Further high-quality research is needed to establish the role of corticosteroids in HELLP syndrome management.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...